Lumos Pharma Inc (LUMO)
4.31
-0.02
(-0.46%)
USD |
NASDAQ |
Nov 22, 10:59
Lumos Pharma Revenue (Quarterly): 0.726M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.726M |
| June 30, 2024 | 0.488M |
| March 31, 2024 | 0.165M |
| December 31, 2023 | 0.826M |
| September 30, 2023 | 0.007M |
| June 30, 2023 | 0.527M |
| March 31, 2023 | 0.691M |
| December 31, 2022 | 0.512M |
| September 30, 2022 | 0.497M |
| June 30, 2022 | 0.514M |
| March 31, 2022 | 0.111M |
| December 31, 2021 | 0.22M |
| September 30, 2021 | |
| June 30, 2021 | 0.01M |
| March 31, 2021 | |
| December 31, 2020 | 0.04M |
| September 30, 2020 | 0.074M |
| June 30, 2020 | 0.033M |
| March 31, 2020 | 0.021M |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.202M |
| September 30, 2018 | 0.12M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.252M |
| March 31, 2018 | 9.90M |
| December 31, 2017 | 28.38M |
| September 30, 2017 | 0.103M |
| June 30, 2017 | 10.37M |
| March 31, 2017 | 2.761M |
| December 31, 2016 | 32.76M |
| September 30, 2016 | 0.888M |
| June 30, 2016 | 2.012M |
| March 31, 2016 | 5.708M |
| December 31, 2015 | 33.95M |
| September 30, 2015 | 0.844M |
| June 30, 2015 | 7.445M |
| March 31, 2015 | 39.20M |
| December 31, 2014 | 172.59M |
| September 30, 2014 | |
| June 30, 2014 | 0.212M |
| March 31, 2014 | 0.334M |
| December 31, 2013 | 1.093M |
| September 30, 2013 | |
| June 30, 2013 | 0.232M |
| March 31, 2013 | 0.302M |
| December 31, 2012 | 1.687M |
| September 30, 2012 | |
| June 30, 2012 | 0.59M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.007M
Minimum
Sep 2023
0.826M
Maximum
Dec 2023
0.3213M
Average
0.22M
Median
Dec 2021
Revenue (Quarterly) Benchmarks
| Boston Scientific Corp | 4.209B |
| Calidi Biotherapeutics Inc | -- |
| NovaBay Pharmaceuticals Inc | 2.441M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -7.467M |
| Total Expenses (Quarterly) | 8.366M |
| EPS Diluted (Quarterly) | -0.90 |
| Enterprise Value | 23.93M |
| Profit Margin (Quarterly) | -1.03K% |
| Earnings Yield | -99.54% |
| Normalized Earnings Yield | -99.54 |